Friday, January 11, 2019 9:04:32 AM
I’m not actually blaming them for the collapse in the SP. I think we all have seen irregular and counter intuitive share trading etc. The science is looking increasingly good and I remain positive on this front. I do however hold them some what responsible for failing to counter this share collapse with a strong positive message and to ensure an environment of strong shareholder support. We have zero upward buying pressure. During this time they have awarded themselves several million options to mitigate dilution and have failed to support the SP. Some non execs have been awarded millions of options individually despite being paid the market rate to execute their day jobs. I fail to see any value to shareholders but I do see a huge benefit to the individual members of our Mgt.
It’s very normal for executive and non executives of public companies to have their incentive plans (LTIPS) or options awarded to them based on delivering the expectations of shareholders. It’s quite normal for a Chair and non execs to set the benefits for the execs but in this case Linda has the role of both Chair and CEO (as well as CFO.)
So we have a CEO (also the Chair) setting the benefits of the non execs who are appointed to serve on the board to protect shareholders and at the same time she also sets the benefits to herself and other executive officers. I have no idea what these non execs have done other than watch over a strategy that has made it especially easy for others to control this stock and for Mgt to benefit themselves ....do any of these guys deserve to be rewarded just because the science works or should they be rewarded because they are delivering an exceptional value to shareholders (which as yet is unproven)
No question about it - nobody should be rewarded based on the science alone. Mgt should be rewarded for setting and executing the strategy of delivering a shareholder return. This especially includes addressing our share price. Benchmarking against competitors with similar results shows that we are sitting at the bottom of the league table despite showing the most promising of any results. We may get a return with the science but that’s down to scientists inventing a vaccine and not because of anything else. It will end when it ends and not before it should and my estimations are March to May for topline and add at least four months to that for a clinical pathway application....so more or less another year before approval. .
The only piece of luck Mgt have had to date (get out of jail card) has been Sawston because of the increase in the value of the land. It could have remained depressed. What would have happened then? Remember this land was never originally bought as a property deal but to create a big pharma company with both manufacturing and research. So the original decision to buy this land was not fundamental to the success of NWBO as is now proven. I am pleased we sold this property and bagged the cash but it was luck and good timing rather than judgement that delivered us from bankruptcy....
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM